ストックスクリーナーアプリを入手
1.06
3.64%
-0.04
前日終値:
$1.10
開ける：
$1.0936
24時間の取引高:
82,074
Relative Volume:
0.26
時価総額：
$18.22M
収益：
-
当期純損益:
$-11.24M
株価収益率:
-1.392
EPS:
-0.7615
ネットキャッシュフロー:
$-4.79M
1週間 パフォーマンス:
-17.19%
1か月 パフォーマンス:
+3.92%
6か月 パフォーマンス:
-8.62%
1年 パフォーマンス:
-3.64%
1日の値動き範囲:
$1.06
$1.11
1週間の範囲:
$1.06
$1.26
52週間の値動き範囲:
$0.51
$5.01
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
MIRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.06 | 18.22M | 0 | -11.24M | -4.79M | -0.7615 |
|
LLY
Lilly Eli Co
|
822.51 | 738.75B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
205.29 | 363.15B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
163.71 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
69.30 | 311.44B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
89.23 | 225.40B | 64.17B | 17.12B | 18.10B | 6.73 |
Mira Pharmaceuticals Inc (MIRA) 最新ニュース
MIRA Pharmaceuticals Inc. (MIRA) reports earnings - Quartz
MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 4.3% – Here’s What Happened - Defense World
MIRA bids for SKNY - The Pharma Letter
MIRA Pharmaceuticals to acquire SKNY for obesity, smoking therapy By Investing.com - Investing.com South Africa
MIRA Pharmaceuticals signs LOI to acquire SKNY Pharmaceuticals - MSN
MIRA Pharmaceuticals to acquire SKNY for obesity, smoking therapy - Investing.com
MIRA Pharmaceuticals to Acquire SKNY in Stock Deal By Investing.com - Investing.com South Africa
MIRA Pharmaceuticals to Acquire SKNY in Stock Deal - Investing.com India
Mira Pharmaceuticals Inc To Acquire Skny PharmaceuticalsSEC Filing -March 24, 2025 at 08:02 am EDT - Marketscreener.com
EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine - Benzinga
MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development - ACCESS Newswire
Major Pharma Deal: MIRA's $5M Backed Entry Into $150B Weight Loss Market - StockTitan
EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug - Yahoo Finance
NRx Pharmaceuticals submits NDA for intravenous ketamine drug - Mugglehead
Mira Pharmaceuticals expands pain management pipeline By Investing.com - Investing.com Australia
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial - Yahoo Finance
Mira Pharmaceuticals Develops Topical Formulation of Ketamir-2 for Pain Relief -March 13, 2025 at 09:30 am EDT - Marketscreener.com
Mira Pharmaceuticals succesfully develops topical version of its therapy for localized neuropathic and inflammatory pain - Marketscreener.com
Mira Pharmaceuticals expands pain management pipeline - Investing.com India
Mira Pharmaceuticals expands Ketamir-2 development with topical treatment - TipRanks
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain - Weatherford Democrat
Revolutionary Topical Pain Treatment: MIRA's Ketamir-2 Targets Multiple Pain Conditions - StockTitan
EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate - Benzinga
What is Zacks Small Cap’s Forecast for MIRA FY2024 Earnings? - Defense World
Mira Pharmaceuticals begins phase 1 trial for pain treatment By Investing.com - Investing.com Australia
SponsoredImpartialComprehensive - Research Tree
Urgent Boots paracetamol recall after packets found to contain a different drug - AOL
Mira Pharmaceuticals Announces Approval And Initiation Of Phase 1 Clinical Trial For Ketamir-2 In Neuropathic Pain - Marketscreener.com
Mira Pharmaceuticals begins phase 1 trial for pain treatment - Investing.com
Mira Pharmaceuticals announces approval, initiation of Phase 1 Ketamir-2 trial - TipRanks
MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain - accessnewswire.com
Can This Novel Ketamine Analog Outperform Gabapentin? MIRA's Neuropathic Pain Drug Enters Clinical Trials - StockTitan
EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain - Benzinga India
Tiziana stock jumps 12% on TBI drug study publication - MSN
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - AOL
Mira Murati's new AI startup poaches 20 OpenAI researchers - Reuters
MediPharm Labs terminates proposed sale of Napanee facility to Kensana Health - Seeking Alpha
Microstrategy Inc. – 8% PRF PERPETUAL USD 100 – Ser A’s (STRK) Stock: A Week-by-Week Analysis - The News Heater
Monday.Com Ltd (MNDY) Shares Down Despite Recent Market Volatility - The News Heater
Mira Pharmaceuticals Inc (MIRA) Stock: Evaluating the Market Performance - The News Heater
Vanda Pharmaceuticals Inc (VNDA) Shares Rise Despite Market Challenges - The News Heater
Air Transport Services Group Inc (ATSG) Stock: Evaluating the Market Performance - The News Heater
Report: OpenAI's ex-CTO, Mira Murati, has recruited OpenAI co-founder John Schulman - Yahoo Finance
OpenAI cofounder John Schulman is joining Mira Murati’s startup after brief stint at Anthropic - Yahoo Finance
Kernel and Mira Launch Industry’s First $300M Secured AI API - GlobeNewswire Inc.
Mira Network Launches $10M Grant Program for AI Builders - EIN News
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy? - AOL
UCalgary researchers to validate Mira Hormone Monitor - Yahoo Finance
TEVA Stock Drops Over 5% Amid Financial Struggles - GuruFocus.com
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End - ACCESS Newswire
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA - ACCESS Newswire
Mira Pharmaceuticals Inc (MIRA) 財務データ
収益
当期純利益
現金流量
EPS
Mira Pharmaceuticals Inc (MIRA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Aminov Erez | Chief Executive Officer |
Nov 20 '24 |
Sale |
1.27 |
44,590 |
56,629 |
1,061,200 |
1.66%
大文字化:
|
ボリューム (24 時間):